TLDR: Veeva Systems has announced the upcoming deployment of AI agents across its comprehensive suite of life sciences applications, commencing in December 2025. The initial phase will focus on commercial applications, with a subsequent expansion into R&D and quality applications throughout 2026. These AI agents, integrated into the Veeva Vault Platform, are designed to provide industry-specific intelligence, leverage large language models from Anthropic and Amazon, and will be offered with usage-based pricing.
PLEASANTON, Calif. – Veeva Systems (NYSE: VEEV), a prominent provider of cloud-based software for the global life sciences industry, today announced its strategic initiative to integrate and roll out advanced AI agents across its application portfolio. The phased deployment is set to begin in December 2025, initially targeting commercial applications, with a broader expansion into research and development (R&D) and quality applications slated for completion throughout 2026.
The initial wave of AI agent availability in December 2025 will support key commercial applications such as Vault CRM and PromoMats. Following this, Veeva plans to extend the AI capabilities to Safety and Quality applications by April 2026. Further rollouts will include Clinical Operations, Regulatory, and Medical applications in August 2026, culminating with Clinical Data applications by December 2026.
These innovative AI agents are meticulously built into the Veeva Vault Platform, ensuring deep integration and secure access to Veeva’s extensive data, documents, and workflows. They are designed to understand specific application contexts, incorporate application-specific prompts, and include robust safeguards tailored for the highly regulated life sciences sector. The underlying technology will utilize large language models (LLMs) from industry leaders such as Anthropic and Amazon, hosted on Amazon Bedrock. For customers seeking greater flexibility, Veeva will also enable the configuration and extension of its delivered AI agents, as well as the creation of custom agents using Veeva-hosted models or customer-provided models on Amazon Bedrock or Microsoft Azure AI Foundry.
Peter Gassner, CEO of Veeva, emphasized the transformative potential of this initiative, stating, “AI will fundamentally change how drugs are developed and how treatment decisions are made at the point of care.” He further articulated the company’s vision, adding, “Our goal with Veeva AI is to help the industry greatly increase innovation and productivity so better medicines reach more patients, faster.”
Also Read:
- Salesforce Bolsters Agentforce AI Capabilities Through Enhanced Partnerships with OpenAI and Anthropic
- Salesforce Bolsters AI Agent Reliability with Strategic Enhancements
Veeva Systems, a company with a market capitalization of $46.7 billion and an impressive gross profit margin of 75.6%, serves over 1,500 customers globally, ranging from large biopharmaceutical corporations to emerging biotech firms. The introduction of these AI agents is expected to further enhance the company’s offerings and solidify its position in the life sciences technology landscape. The pricing model for these AI agents will be usage-based, designed to facilitate easier adoption and scalability for customers over time.
